Skip to main content

Table 3 Prognostic factors of post-recurrence survival

From: Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy

Variable

Univariate Analysis

Multivariate Analysis

 

HR (95% CI)

p value

OR (95% CI)

p value

Age (≥ 60 vs. <  60 yrs)

1.42 (0.77–2.61)

0.259

 

Sex (male vs. female)

0.05 (0.01–22.32)

0.329

Charlson Comorbidity Index (≥1 vs. 0)

1.18 (0.66–2.11)

0.575

Performance status (1 vs. 0)

1.25 (0.68–2.32)

0.475

Tumor location

(U/M third vs. L third/EGJ)

1.26 (0.68–2.32)

0.457

Tumor length

0.97 (0.82 ~ 1.14)

0.697

Neoadjuvant therapy (yes vs. no)

0.96 (0.51–1.78)

0.885

(y)p T stage (T3 vs. T0–2)

2.03 (1.13–3.65)

0.018

2.53 (1.36–4.71)

0.003

(y)p N stage (N+ vs. N0)

1.39 (0.77–2.49)

0.270

 

Differentiation

(poorly vs. well + moderately)

1.88 (0.78–4.53)

0.161

LVI (+ vs. -)

1.32 (0.74–2.36)

0.353

PNI (+ vs. -)

1.71 (0.76–3.86)

0.197

TRG (0 vs. 1–3)

0.59 (0.24–1.41)

0.244

CRM (involved or close vs. uninvolved)

1.34 (0.63 ~ 2.84)

0.440

Disease free interval (>  12 vs. ≤ 12 months)

0.65 (0.36–1.17)

0.149

Recurrence pattern

 

 Distant vs. loco-regional

0.81 (0.45–1.45)

0.475

 Lung (with vs. without)

0.60 (0.31–1.15)

0.125

 Liver (with vs. without)

1.02 (0.32–03.32)

0.967

 Bone (with vs. without)

1.89 (0.450–7.88)

0.382

 Brain (with vs. without)

2.69 (0.81–8.88)

0.105

 Pleural/Chest wall

(with vs. without)

0.95 (0.33–2.69)

0.923

 Cervical lymph node

(with vs. without)

0.85 (0.39–1.83)

0.676

 Mediastinum

(with vs. without)

2.79 (1.35–05.75)

0.005

3.81 (1.76–8.26)

0.001

 Anastomosis

(with vs. without)

0.41 (0.10–1.78)

0.236

 

 Operation for recurrence

(yes vs. no)

0.61 (0.34 ~ 1.11)

0.107

  1. HR Hazard ratio, CI Confidence interval, U Upper, M Middle, L Lower, EGJ Esophagogastric junction, LVI Lymphovascular invasion, PNI Perineural invasion, TRG Tumor regression grade, CRM Circumferential resection margin